Category: <span>Verastem</span>

Category: Verastem

alimta, COMMAND, Data Safety Monitoring Board, Defactinib, focal adhesion kinase, Joseph Pantgins, Lou Vaickus, malignant pleural mesothelioma, mesothelioma clinical trials, Mesothelioma News, Robert Forrester, Verastem, VS-4718, VS-5584, VS-6063

Verastem Mesothelioma Clinical Trial Stopped Early For Futility

 

The Boston-based company Verastem has stopped its mesothelioma clinical trial early due to futile results in the Phase 2 study of VS-6063.

asbestos, cancer, Cape Town, conference, FAK, focal adhesion kinase, iMig, Inc., inhibitor, International Mesothelioma Interest Group, merlin, Mesothelioma News, South Africa, stem cell, target, tumor suppressor, Verastem, VS-6063

Research Team to Give Exciting Presentations at Mesothelioma Conference in South Africa

 

Drug Developer to Present New Data at Annual Mesothelioma Conference

asbestos, asbestos exposure, cancer, FAK, focal adhesion kinase, Inc., merlin, mesothelioma, Mesothelioma News, mesothelioma symptoms, Science Translational Medicine, stem cell, Verastem

Cancer Drug Developer Verastem Publishes Paper on Study of Merlin Loss

 

Scientists Publish Paper Declaring Merlin Deficiency as Predictor of Cancer Drugs’ Efficacy